Scientific Sessions 2024  /  Post Acute Management in the ACS Population  /  Real World Data From A Nationwide Survey: Current Approaches Post Acute Coronary Syndromes By Cardiologists
Logo

American Heart Association

  161
  0

Final ID: MDP731

Real World Data From A Nationwide Survey: Current Approaches Post Acute Coronary Syndromes By Cardiologists

Abstract Body (Do not enter title and authors here): Background: A new ESC guidelines in 2023, the International Lipid Expert Panel (ILEP) 2021 recommendations, and a subsequent statement by EAS have been published based on recent advances in lipid lowering treatments. However, real world data are lacking regarding the implementation among the community of French cardiologists.

Objective: To determine the current approach and therapeutic strategies concerning lipid lowering treatments post-acute coronary syndromes in France.

Methods: This national survey was performed during October and November 2023 in France with an online questionnaire on the websites of 2 national French Societies of Cardiologists.
Four mailings were sent to cardiologists to invite them to answer to the questionnaire. A total of 400 answers of cardiologists were collected during this 2-month period.

Results: For ASCVD patients, cardiologists agreed with an LDL-C goal below 55 mg/dL (1.4 mmol/L) in 69%, below 70 mg/dL (1.8 mmol/L) in 16.5%, and 14.5% between 70 mg/dL and 100 mg/dL (1.8-2.5 mmol/L). An upfront lipid lowering combination strategy using fixed dose combination (FDC) of statins and ezetimibe was prescribed in less than 5% of patients, whereas high-intensity statins were prescribed in more than 90% of patients. No significant differences were observed in terms of sex of patients, geographical area, or strategies followed by male and female cardiologists (p > 0.05). A combination of statins and ezetimibe was prescribed only for a minority of patients, especially as an early upfront strategy. The use of PCSK9i remains marginal and the interval between the ACS and initiation of these medicines remains high.

Conclusion: In this contemporary national survey, we report an excellent agreement of lipid goals in secondary prevention by cardiologists. Despite the declared consensus recommending a low LDL-C target in ACS patients, lipid lowering strategies are suboptimal, mainly consisting of high intensity statins. The lack of recommended use of ezetimibe and PCSK9i to lower LDL-C levels highlights the importance of better implementation of intensive and early upfront strategies to reduce recurrent ischemic events.
  • Sabouret, Pierre  ( PITIE SALPETRIERE-HEART INSTITUTE , Paris , France )
  • Santos, Raul  ( University of Sao Paulo , Sao Paulo , Brazil )
  • Sharareh, Ali  ( Collège National des Cardiologues Français , Paris , France )
  • Garban, Thierry  ( Collège National des Cardiologues Français , Paris , France )
  • Cohen, Serge  ( Collège National des Cardiologues Français , Paris , France )
  • Parrens, Eric  ( Collège National des Cardiologues Français , Paris , France )
  • Villaceque, Marc  ( Collège National des Cardiologues Français , Paris , France )
  • Guedjmeynier, Dominique  ( Collège National des Cardiologues Français , Paris , France )
  • Lequeux, Benoit  ( Collège National des Cardiologues Français , Paris , France )
  • Olivier, Hoffman  ( Collège National des Cardiologues Français , Paris , France )
  • Dib, Jean-claude  ( Affiliation Groupe hospitalier privé , Paris , France )
  • Durand, Philippe  ( Collège National des Cardiologues Français , Paris , France )
  • Bernardi, Marco  ( Clinique Saint-Joseph , Trelaze , France )
  • Spadafora, Luigi  ( Clinique Saint-Joseph , Trelaze , France )
  • Asher, Elad  ( Shaare Zesek Medical Center , Karmey Yosef , Israel )
  • Bhatt, Deepak  ( Mount Sinai Fuster Heart Hospital , New York , New York , United States )
  • Biondi-zoccai, Giuseppe  ( Sapienza University of Rome , Rome , Italy )
  • Banach, Maciej  ( Medical University of Lodz , Lodz , Poland )
  • Amara, Walid  ( GHI Le Raincy-Montfermeil , Montfermeil , France )
  • Schiele, Francois  ( Hopital Jean Minjoz , Besancon , France )
  • Lellouche, Nicolas  ( Hôpital henri mondor , Creteil , France )
  • Dievart, Francois  ( Collège National des Cardiologues Français , Paris , France )
    • Author Disclosures:
    Pierre SABOURET: DO have relevant financial relationships ; Consultant:AXIS TX:Active (exists now) ; Speaker:PFIZER:Past (completed) ; Speaker:NOVONORDISK:Past (completed) ; Speaker:SANOFI:Active (exists now) ; Speaker:Astra-Zeneca:Expected (by end of conference) | HOFFMAN Olivier: DO NOT have relevant financial relationships | Jean-Claude Dib: No Answer | PHILIPPE DURAND: DO NOT have relevant financial relationships | Marco Bernardi: No Answer | Luigi Spadafora: No Answer | Elad Asher: DO NOT have relevant financial relationships | Deepak Bhatt: DO have relevant financial relationships ; Advisor:Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys:Active (exists now) ; Other (please indicate in the box next to the company name):Trustee: American College of Cardiology; Unfunded Research: FlowCo:Active (exists now) ; Other (please indicate in the box next to the company name):Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions;:Active (exists now) ; Royalties/Patent Beneficiary:Royalties: Elsevier (Editor, Braunwald’s Heart Disease):Active (exists now) ; Researcher:Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio;:Active (exists now) ; Royalties/Patent Beneficiary:Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria: Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee);:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum):Active (exists now) ; Other (please indicate in the box next to the company name):Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);:Active (exists now) ; Consultant:Broadview Ventures, GlaxoSmithKline, Hims, SFJ, Youngene:Active (exists now) ; Other (please indicate in the box next to the company name):Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock);:Active (exists now) | Giuseppe Biondi-Zoccai: DO have relevant financial relationships ; Consultant:Abiomed:Past (completed) ; Consultant:Translumina:Past (completed) ; Consultant:Terumo:Past (completed) ; Consultant:Microport:Past (completed) ; Consultant:Menarini:Past (completed) ; Consultant:Meditrial:Past (completed) ; Consultant:Innovheart:Past (completed) ; Consultant:Guidotti:Past (completed) ; Consultant:Eukon:Past (completed) ; Consultant:Endocore Lab:Past (completed) ; Consultant:Crannmedical:Past (completed) ; Consultant:Cardionovum:Past (completed) ; Consultant:Balmed:Past (completed) ; Consultant:Amarin:Past (completed) ; Consultant:Aleph:Past (completed) | Maciej Banach: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen, Daichii-Sankyo, Mylan, and Sanofi:Past (completed) ; Speaker:Adamed, Amgen, Daiichi-Sankyo, Exceed-Pharma, Kogen, KRKA, MSD, NewAmsterdam, Novartis, Novo-Nordisk, Polpharma, Sanofi, Servier, Teva, Viatris and Zentiva:Active (exists now) ; Consultant:Adamed, Amgen, Daiichi-Sankyo, Esperion, MSD, NewAmsterdam, Novartis, Novo-Nordisk, Sanofi, Teva, Viatris:Active (exists now) | Walid Amara: DO NOT have relevant financial relationships | Raul Santos: DO have relevant financial relationships ; Consultant:Sanofi/Regeneron:Past (completed) ; Speaker:PTC:Active (exists now) ; Researcher:PTC:Active (exists now) ; Speaker:Amgen:Active (exists now) ; Researcher:Esperion:Past (completed) ; Researcher:Kowa:Past (completed) ; Consultant:Amryt:Past (completed) ; Speaker:Libbs:Past (completed) ; Speaker:Novo Nordisk:Active (exists now) ; Consultant:Novo Nordisk:Past (completed) ; Researcher:Novartis:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Researcher:Sanofi/Regeneron:Past (completed) ; Speaker:Sanofi/Regeneron:Active (exists now) | Francois Schiele: No Answer | Nicolas Lellouche: DO NOT have relevant financial relationships | Francois Dievart: No Answer | Ali Sharareh: No Answer | thierry garban: No Answer | Serge Cohen: No Answer | Eric Parrens: No Answer | Marc Villaceque: No Answer | Dominique Guedjmeynier: No Answer | Benoit Lequeux: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Post Acute Management in the ACS Population

Saturday, 11/16/2024 , 02:50PM - 04:05PM

Moderated Digital Poster Session

More abstracts on this topic:
A Polypill Strategy for Lipid Lowering and Anti-Platelet Therapy After Acute Coronary Syndrome: A Pilot Randomized Controlled Trial

Keshvani Neil, Wang Thomas, Pandey Ambarish, Coellar Juan David, Rizvi Syed Kazim, Jain Anand, Bustillo-rubio M. Karina, Segar Matthew, Lokesh Nidhish, Miller James, Yates Sean

A Case of Recurrent Acute Coronary Syndrome and Cardiogenic Shock due to Apolipoprotein A-IV Amyloidosis

Muthukkumar Rashmi, Holmes Taylor, Friede Kevin

More abstracts from these authors:
Cardiologist Attitude to Lipid Control in Patients with ASCVD without Major Cardiovascular Events: Insights from the 2024 ACS EuroPath Survey

Zaman Azfar, De Caterina Raffaele, Schiele Francois, Sionis Alessandro, Catapano Alberico, Laufs Ulrich

The Restricted Fluid Intake Compared With Liberal Fluid Intake In Patients With Heart Failure – A Meta-Analysis

Bielecka-dabrowa Agata, Banach Maciej, Jaiswal Vikash

You have to be authorized to contact abstract author. Please, Login
Not Available